Bioactive Small Molecules
Apexbio Technology LLC Tasquinimod, 10mg. Cas: 254964-60-8 MFCD: MFCD18251454. Antiangiogenic and antineoplastic agent
Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic ability that has shown promise in the treatment of advanced prostate cancers [1]. Other sizes are available. Please inqury us for quote.
Apexbio Technology LLC Tasquinimod, 50mg. Cas: 254964-60-8 MFCD: MFCD18251454. Antiangiogenic and antineoplastic agent
Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic ability that has shown promise in the treatment of advanced prostate cancers [1]. Other sizes are available. Please inqury us for quote.
Apexbio Technology LLC LY3200882 1898283-02-7 50mg
LY3200882 (CAS 1898283-02-7) is a small-molecule therapeutic currently being evaluated in preclinical and clinical oncology research Its mechanism of action involves modulation of signaling pathways relevant to tumor immune evasion potentially enhancing antitumor immune responses Present research focuses on clinical assessment of LY3200882 combined with pembrolizumab an immune checkpoint inhibitor in patients with advanced cancers (clinical trial NCT04158700) This investigation aims to clarify LY3200882 s immunomodulatory role and therapeutic potential in oncology
Apexbio Technology LLC CYT997 (Lexibulin) 917111-44-5 5mg
CYT997 (Lexibulin CAS 917111-44-5) is a small molecule inhibitor that disrupts microtubule polymerization By targeting microtubule dynamics CYT997 impairs mitotic progression and induces apoptosis in cancer cells The compound exhibits potent antiproliferative activity in vitro with reported IC50 values ranging from 10 to 100 nM across various cancer cell lines CYT997 has advanced to Phase 1/2 clinical evaluation highlighting its potential as a research tool for investigating microtubule function and exploring novel strategies for anticancer drug development
Apexbio Technology LLC Cy3.5 azide (non-sulfonated), 25mg. Cas: MFCD: NA. used for Click chemistry to label alkyne-modified oligonucleotides
Cy3.5 azide is a solid material dye ready for the use in Click Chemistry reaction. Most derivatives of non-sulfonated cyanines have low aqueous solubility except for hydrochlorides of hydrazides and amines Other sizes are available. Please inqury us for quote.
Apexbio Technology LLC Cy3.5 azide (non-sulfonated), 5mg. Cas: MFCD: NA. used for Click chemistry to label alkyne-modified oligonucleotides
Cy3.5 azide is a solid material dye ready for the use in Click Chemistry reaction. Most derivatives of non-sulfonated cyanines have low aqueous solubility except for hydrochlorides of hydrazides and amines Other sizes are available. Please inqury us for quote.
Apexbio Technology LLC RO4929097(Synonyms: RO-4929097, RO 4929097, Gamma-Secretase Inhibitor RO4929097, RO4929097 γ-secretase inhibitor), 5mg, CAS: 847925-91-1.
RO4929097 (CAS 847925-91-1) is a potent selective small-molecule inhibitor of -secretase an essential protease in the Notch signaling pathway It inhibits -secretase with high specificity (IC50 4 nM EC50 5 nM) showing minimal inhibitory activity against closely related proteases and over 100-fold selectivity versus a broad spectrum of other proteases By preventing Notch receptor cleavage and subsequent signaling activation RO4929097 suppresses proliferation and tumorigenesis across various tumor models including melanoma breast colorectal pancreatic and lung cancers Clinical studies have assessed RO4929097 alone or combined with other anticancer agents for advanced solid tumors
Apexbio Technology LLC AZD 3965(Synonyms: AZD3965, AZD-3965, CAS 1448671-31-5, MCT1 inhibitor AZD3965, AZD3965 MCT1 inhibitor), 25mg, CAS: 1448671-31-5.
AZD 3965 (CAS 1448671-31-5) is a potent inhibitor of monocarboxylate transporter 1 (MCT1) exhibiting a Ki value of 1 6 nM MCT1 inhibition disrupts lactate transport especially in tumor cells lacking monocarboxylate transporter 4 (MCT4) hindering tumor lactate metabolism under hypoxic conditions In vitro studies demonstrated AZD 3965 sensitivity increases significantly under hypoxia and confirmed its MCT1 specificity in engineered cell lines In vivo experiments in COR-L103 xenograft models showed suppressed tumor growth without tumor regression AZD 3965 is currently under clinical investigation in phase I trials involving advanced cancer patients
Apexbio Technology LLC Pemetrexed disodium hemipenta hydrate 357166-30-4 100mg
Pemetrexed disodium hemipenta hydrate (CAS 357166-30-4) is a multitargeted antifolate that inhibits key enzymes in folate metabolism including thymidylate synthase (TS) dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT) with Ki values for its pentaglutamate form of 1 3 nM 7 2 nM and 65 nM respectively Compared to the monoglutamate form the pentaglutamate exhibits enhanced inhibitory potency particularly against TS and GARFT Pemetrexed is approved for the treatment of advanced non-squamous non-small cell lung cancer In preclinical models it additionally modulates renal uptake of radiolabeled folates These features support its utilization in studies of folate pathway inhibition and cancer therapy
Apexbio Technology LLC AZD 3965(Synonyms: AZD3965, AZD-3965, CAS 1448671-31-5, MCT1 inhibitor AZD3965, AZD3965 MCT1 inhibitor), 5mg, CAS: 1448671-31-5.
AZD 3965 (CAS 1448671-31-5) is a potent inhibitor of monocarboxylate transporter 1 (MCT1) exhibiting a Ki value of 1 6 nM MCT1 inhibition disrupts lactate transport especially in tumor cells lacking monocarboxylate transporter 4 (MCT4) hindering tumor lactate metabolism under hypoxic conditions In vitro studies demonstrated AZD 3965 sensitivity increases significantly under hypoxia and confirmed its MCT1 specificity in engineered cell lines In vivo experiments in COR-L103 xenograft models showed suppressed tumor growth without tumor regression AZD 3965 is currently under clinical investigation in phase I trials involving advanced cancer patients
Apexbio Technology LLC MK-0752(Synonyms: MK0752, MK 0752, MK-752, MK752, Gamma-secretase inhibitor MK-0752), 50mg, CAS: 471905-41-6.
MK-0752 (CAS 471905-41-6) is a small molecule inhibitor of -secretase an enzymatic complex responsible for proteolytic cleavage of the Notch receptor -secretase-mediated cleavage releases the Notch intracellular domain (NICD) thereby activating gene transcription essential for cellular differentiation proliferation and survival MK-0752 potently inhibits -secretase enzymatic activity with an IC50 of approximately 50 nM In vitro inhibition of -secretase by MK-0752 suppresses proliferation of breast cancer cells This compound has been investigated in clinical studies for advanced breast cancer and other solid tumors as well as pediatric refractory CNS malignancies underscoring its relevance for oncology research targeting Notch signaling
Apexbio Technology LLC MK-0752(Synonyms: MK0752, MK 0752, MK-752, MK752, Gamma-secretase inhibitor MK-0752), 5mg, CAS: 471905-41-6.
MK-0752 (CAS 471905-41-6) is a small molecule inhibitor of -secretase an enzymatic complex responsible for proteolytic cleavage of the Notch receptor -secretase-mediated cleavage releases the Notch intracellular domain (NICD) thereby activating gene transcription essential for cellular differentiation proliferation and survival MK-0752 potently inhibits -secretase enzymatic activity with an IC50 of approximately 50 nM In vitro inhibition of -secretase by MK-0752 suppresses proliferation of breast cancer cells This compound has been investigated in clinical studies for advanced breast cancer and other solid tumors as well as pediatric refractory CNS malignancies underscoring its relevance for oncology research targeting Notch signaling
Apexbio Technology LLC AZD 3965(Synonyms: AZD3965, AZD-3965, CAS 1448671-31-5, MCT1 inhibitor AZD3965, AZD3965 MCT1 inhibitor), 10mg, CAS: 1448671-31-5.
AZD 3965 (CAS 1448671-31-5) is a potent inhibitor of monocarboxylate transporter 1 (MCT1) exhibiting a Ki value of 1 6 nM MCT1 inhibition disrupts lactate transport especially in tumor cells lacking monocarboxylate transporter 4 (MCT4) hindering tumor lactate metabolism under hypoxic conditions In vitro studies demonstrated AZD 3965 sensitivity increases significantly under hypoxia and confirmed its MCT1 specificity in engineered cell lines In vivo experiments in COR-L103 xenograft models showed suppressed tumor growth without tumor regression AZD 3965 is currently under clinical investigation in phase I trials involving advanced cancer patients
Apexbio Technology LLC MK-0752(Synonyms: MK0752, MK 0752, MK-752, MK752, Gamma-secretase inhibitor MK-0752), 10mM (in 1mL DMSO), CAS: 471905-41-6.
MK-0752 (CAS 471905-41-6) is a small molecule inhibitor of -secretase an enzymatic complex responsible for proteolytic cleavage of the Notch receptor -secretase-mediated cleavage releases the Notch intracellular domain (NICD) thereby activating gene transcription essential for cellular differentiation proliferation and survival MK-0752 potently inhibits -secretase enzymatic activity with an IC50 of approximately 50 nM In vitro inhibition of -secretase by MK-0752 suppresses proliferation of breast cancer cells This compound has been investigated in clinical studies for advanced breast cancer and other solid tumors as well as pediatric refractory CNS malignancies underscoring its relevance for oncology research targeting Notch signaling
Apexbio Technology LLC MK-0752(Synonyms: MK0752, MK 0752, MK-752, MK752, Gamma-secretase inhibitor MK-0752), 100mg, CAS: 471905-41-6.
MK-0752 (CAS 471905-41-6) is a small molecule inhibitor of -secretase an enzymatic complex responsible for proteolytic cleavage of the Notch receptor -secretase-mediated cleavage releases the Notch intracellular domain (NICD) thereby activating gene transcription essential for cellular differentiation proliferation and survival MK-0752 potently inhibits -secretase enzymatic activity with an IC50 of approximately 50 nM In vitro inhibition of -secretase by MK-0752 suppresses proliferation of breast cancer cells This compound has been investigated in clinical studies for advanced breast cancer and other solid tumors as well as pediatric refractory CNS malignancies underscoring its relevance for oncology research targeting Notch signaling